Peptides for Pulmonary Fibrosis: Targeting Scarring and Inflammation

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies are emerging as promising treatments for pulmonary fibrosis, a debilitating lung disease characterized by scarring. Peptides like ToAP3, ToAP4, Ac-SDKP, and LTI-03 demonstrate antifibrotic and anti-inflammatory effects, offering novel approaches to mitigate disease progression and preserve lung function.

Peptides: A New Frontier in Pulmonary Fibrosis Treatment

Pulmonary fibrosis (PF), particularly idiopathic pulmonary fibrosis (IPF), is a severe and progressive lung disease marked by irreversible scarring and declining lung function. Traditional treatments often fall short in halting disease progression. However, innovative research is revealing the potential of various peptides to intervene in the fibrotic process, offering new hope for patients.

Immunomodulatory Peptides: ToAP3 and ToAP4

Immunomodulatory peptides like ToAP3 and ToAP4, derived from Tityus obscurus venom, have shown significant promise in preclinical models. A 2023 study by Simon et al. demonstrated that these peptides could delay the inflammatory process and regulate fibrotic-associated cytokine production in a bleomycin-induced murine model of IPF. They maintained tissue characteristics and standard lung function properties, suggesting their potential as therapeutic alternatives or adjuvants for IPF. These peptides achieve their effects by regulating the immune response, specifically by interfering with inflammatory pathways and cytokine expression.

Antifibrotic Peptides: Ac-SDKP and LTI-03

Other peptides, such as N-acetyl-seryl-aspartyl-proline (Ac-SDKP), have been identified for their direct antifibrotic properties. Ac-SDKP, along with PAP and DEL-1, has been shown to affect lung epithelial cells, leading to the inhibition of TGF-β activation—a key driver of fibrosis (Karande et al., 2023). This mechanism helps prevent the excessive collagen deposition that characterizes fibrotic lung tissue. Additionally, LTI-03, a novel peptide from Rein Therapeutics, has demonstrated anti-fibrotic activity in ex vivo lung models and shows potential for reducing fibrosis and preserving lung cells in IPF patients (MacKenzie et al., 2025; Rare Disease Advisor, 2025).

Targeting Scar Tissue: Peptide Mimics and Collagen-Mimetic Peptides

Beyond direct antifibrotic actions, some peptides are designed to target or mimic components of scar tissue. Research has explored peptide mimics of proteins like Thy-1, which is crucial for the resolution of scar tissue (YouTube, 2024). Furthermore, collagen-mimetic peptides, such as LyP-1, are being investigated for their ability to detect irregular collagen matrices, offering potential for improved diagnostic accuracy and timely intervention in pulmonary fibrosis (Nature, 2025). These approaches highlight a dual strategy: not only preventing new fibrosis but also addressing existing scar tissue.

Peptide Delivery and Future Directions

The efficacy of peptide therapies for lung diseases often depends on effective delivery. Inhalable stealth liposomes are being developed to improve peptide delivery to the lungs, enhancing their therapeutic potential while minimizing systemic toxicity (Lin et al., 2026). This focus on targeted delivery is crucial for maximizing the benefits of these novel agents. While nintedanib and pirfenidone are current antifibrotic drugs, they only slow disease progression and have significant side effects. Peptides, with their diverse mechanisms, offer the potential for more precise interventions with potentially fewer adverse effects, though extensive clinical trials are still needed.

Clinical Takeaway

Peptide-based therapies represent a significant advancement in the fight against pulmonary fibrosis. By targeting key pathways involved in inflammation, scarring, and immune regulation, these agents offer a more nuanced and potentially more effective approach than current treatments. The development of immunomodulatory and antifibrotic peptides, coupled with improved delivery methods, paves the way for future therapies that could not only slow but potentially reverse the devastating effects of pulmonary fibrosis, ultimately improving patient outcomes and quality of life.